TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $80
TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $68 to $80.

Last updated: 2026-11-19 02:29:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Royalty Pharma plc (RPRX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $68.67, with a market capitalization of $30.51B and a P/E ratio of 45.54. Over the past 52 weeks, its price has ranged from $37.31 to $70.37. This page covers its latest market performance, valuation, price trends and company information.
$30.51B | |
$68.57 | |
$69.69 | |
$68.14 | |
$68.68 | |
2.51M | |
3.19M | |
45.54 | |
$70.37 | |
$37.31 | |
1.34% | |
2026-09-30 |
Royalty Pharma plc (RPRX) last closed at $68.67 as of 2026-11-19 00:58:00, up 0.15% ($0.10) from the previous close of $68.68.
During the latest regular trading session, RPRX traded between $68.14 and $69.69, with a volume of 2.51M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Royalty Pharma plc (RPRX) moved from $68.77 to $68.67, representing a decline of 0.14% ($0.10).
The stock traded between $66.93 and $70.37 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 3.33 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 94.9%
RPRX is currently trading at $68.67, placing it 94.9% of the way from its 52-week low of $37.31 to its 52-week high of $70.37. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 100 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Royalty Pharma plc.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 13, 2026 |
| Payment Date | Dec 10, 2026 |
| Dividend Per Share | $0.235 |
Latest news related to Royalty Pharma plc and RPRX stock.
TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $68 to $80.
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 6.93% on an annualized basis producing an average annual return of 19.95%. Currently, Royalty Pharma has a market capitalization of
Eligible investors can buy real shares of Royalty Pharma plc (RPRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to RPRX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between RPRX shares and USD.
RPRX Shares to USD
1.00 RPRX shares = 68.674 USD
Calculations are estimates based on the latest available price and are for reference only.